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Abstract
Background: Coronary Artery Disease (CAD) is caused by the blockage of the coronary arteries. it is argued that
there has an association between the Interleukin-6 gene and the occurrence of atherosclerosis, coronary artery
disease, Due to the short half-life and high variability of Interleukin-6 (IL-6), limited studies have been performed on
the association of serum levels of interleukin-6 with coronary artery disease. The aim of this study is to investigate
the relationship between IL-6 gene polymorphisms and coronary artery disease.
Methods: This study was conducted as a meta-analysis of selected articles with no lower time limit and upto
March 2020. Articles related to the subject were obtained by searching several data sources,such as the SID,
IranDoc, Scopus, Embase, Web of Science (ISI), PubMed, Science Direct, and Google Scholar databases. The
heterogeneity of the studies was assessed using the I2 index in the Comprehensive Meta-Analysis software.
Results: The GG genotype of the IL-6174 G> C polymorphism with a 0.8 odds ratio tended to reduce the risk of
CAD by 20%. The odds ratio of CAD in CG and GG genotypes were found to be 1.16 and 1.48 times respectively,
indicating the increasing effect of these two genotypes. In the IL-6-572 C>G polymorphism, CG and GG genotypes
increased the risk of CAD by 1.21 and 1.27 times respectively, and the CC genotype tended to reduce the risk of
CAD by 15%, considering the odds ratio of 0.85.
Conclusion: This study showed a relationship between IL-6174G> C and Interleukin-6 (IL-6) 572 C>G genes and
coronary artery disease. Moreover, the protective effects of GG genotype in IL-6 gene 174 G> C and CC genotype in
IL-6 gene 572 C>G gene were reported. The study also confirmed that the CG and CC genotypes of the G>C IL-
6174 gene have an increasing effect on coronary artery disease. Moreover, CG and GG genotypes in the IL-6 gene
572 C>G increased the risk of developing CAD. It should be noted that the increased risk of developing CAD was
limited to meta-analytic studies in reported literatures.
Keywords: Coronary artery disease, Polymorphism, Cardiovascular disease, IL-6174 G> C, IL-6 -572C> G,
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Background
Cardiovascular diseases are known to be a leading dis-
order that embrace a wide range of specific diseases such
as vascular disorders, Myocardial Infarction (MI), and
congenital heart disease. In fact, such diseases involve dis-
orders of the cardiovascular and blood circulation systems.
Cardiovascular diseases are known to be a top cause of
human mortality worldwide. Studies have shown that car-
diovascular disorders are more likely to cause death in the
general population than other diseases such as infectious
diseases, maternal and infant diseases, nutritional disor-
ders, and cancers [1–4]. The mortality rate from cardio-
vascular diseases is reported to be 45% [5]. The constant
accumulation of fat, immune cells, and fibrous tissues in
the lining of the arteries can block the arteries. This can
lead to decreased alertness, decreased blood flow, and
eventually a cardiovascular disease [6].
Atherosclerosis is a cardiovascular disorder and a
chronic inflammatory response by the body that has
stable and unstable periods. This disorder occurs in the
large and medium arteries. The cause of this disease is
fat and cholesterol accumulation in the wall of the arter-
ies [7, 8]. Atherosclerotic lesions are caused by asymmet-
ric thickening of the inner layer of the arteries [9]. Acute
Coronary artery Syndrome (ACS), Coronary Artery Dis-
ease (CAD), Myocardial Infarction (MI), stable and un-
stable angina, stroke, transient ischemic attack and
peripheral arterial disease are known as atherosclerotic
subunits [10].
Coronary Artery Disease (CAD) is caused by a block-
age of the coronary arteries. The disease can cause myo-
cardial ischemia and eventually necrosis of the heart.
CAD is considered the leading cause of death in differ-
ent populations. The formation of atherosclerotic pla-
ques is a major factor in the advancement of CAD.
Although the the mechanism is not unknow and the re-
search of that is limited, the role of inflammation in the
occurrence of atherosclerotic plaques cannot be ignored
[11]. Angina and myocardial infarction can be consid-
ered as some of the clinical indicators of this disorder
[11–13]. Several types of immune cells, including macro-
phages,and T and B lymphocytes also accumulate in the
arterial walls and are involved in the development of
atherosclerotic disorders through cytokines and other
mediators [14].
Cytokines are small proteins that, in addition to the
immune system, have a wide range of physiological roles.
These proteins are produced by different types of cells.
Functional pleiotropy is one of the characteristics of this
group of materials and makes cytokines able to play a
regulatory role in cell differentiation and proliferation
activities according to cell type and status. Different
types of cytokines include interleukins, interferon, and
growth factors [15, 16].
There are several factors that contribute to coronary
artery disease. However, these factors vary from one per-
son to another. Genetics is considered to be one of the
factors influencing the development of CAD. Some stud-
ies have reported 50 risk points in the human genome
that can influence CAD development [17]. Extensive
genomic studies demonstrate that genetic factors in-
crease the chances of developing CAD by 1.1 to 1.3
times [18]. It has also been shown that hereditary factors
account for 30–60% of interpersonal differences in CAD
[19]. The severity of the genetic effect depends on fac-
tors such as the age of the person at the onset point and
also the type of disease [4].
The Interleukin-6 (IL-6) encoding gene is located on
the 7P21 chromosome and contains 6 exons. Most stud-
ies have focused on the Interleukin-6 (IL-6) gene pro-
moter region. This is because many single-nucleotide
polymorphisms, such as IL-6-1744 G / C polymor-
phisms, IL-6 -572 C / G, and IL-6 -598, are located in
this region [20]. Sie et al. (2006) argue that IL-6174 poly-
morphism is effective in transcribing the Interleukin-6
(IL-6) gene and, consequently, in the plasma level of IL-
6 [21]. On the other hand, it is argued that there has
been an association between the IL-6572 gene and the
occurrence of atherosclerosis, coronary artery disease,
and MI [22].
IL-6 is the main stimulus for the acute phase response
and stimulates liver synthesis and enhances the C-
reactive protein (CRP) [23]. This protein is a precursor
to vascular atheromatobiotic disease and is involved in
the pathogenesis of atherosclerosis. Elevated plasma
levels of IL-6 and CRP increase the risk of death in the
elderly. On the other hand, serum IL-6 levels are high in
people with unstable angina, which is a symptom of cor-
onary artery disease [23–25].
IL-6 is known as a cytotoxic polytropic. This protein is
involved in activities such as activating macrophages,
stimulating B and T cells, and thymocytes in the process
of differentiation, regulating restorative activities, and
replicating and inducing the activities of the immune
system, and the cardiovascular and nervous systems.
Interleukin-6 family of proteins include Leukemia In-
hibitory Factor (LIF), cardiothropin-1 (CT-1), IL-6, and
IL-11. Interleukin-6 is expressed by tissue immune cells.
Cardiovascular cells such as endothelial cells, smooth
muscle cells, and ischemic myocytes also play a part in
the expression of IL-6 proteins [15, 16, 23, 26] (Fig. 1).
IL-6 connects to its membrane receptor; This receptor
consists of two sub-units IL-6 and gpl30. Once IL-6 is
connected to IL-6R, it activates soluble IL-6R. The IL-6_
SIL-6R complex as a potent agonist activates Glycopro-
tein 130 (a signal transmission component), and this
process enhances the IL-6 mechanism. IL-6 plays an im-
portant role as a mediator of inflammation.
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Due to the short half-life and high variability of
Interleukin-6 (IL-6), limited studies have been per-
formed on the association of serum levels of interleukin-
6 with coronary artery disease [27]. Moreover, the inter-
actions between cardiovascular risk factors, inflamma-
tory mechanism and atheromatosis are complex [25].
Given the importance of recognizing people prone to
heart disease, the risks associated with the disease and
since the disease has a high mortality rate, Knowing the
factors that affect its occurrence can be effective in
macro-planning to control and prevent the occurrence
of the disease and its complications in different popula-
tions. In this study, the relationship between IL-6 gene
polymorphism and coronary artery disease is examined.
Methods
Search method
This study was performed to determine the relationship
between cytokine gene polymorphism and cardiovascu-
lar disorders by systematic review and meta-analysis. To
collect data in this study, Iranian and international data-
bases of Embase, Scopus, Web of Science, PubMed, Sci-
ence Direct, ProQuest, Google Scholar, SID, and Irandoc
were searched. Search process in the above-mentioned
databases were conducted using the keywords: (“Inter-
leukin gene” OR “ Interleukin-6 (IL-6) gene” OR “IL-6
polymorphism” OR “IL-174G / C OR 572C / G OR
597G / A OR IL-6R OR RS1800795 OR RS1800796 OR
RS1800797 OR “cytokine gene“) AND (“cardiovascular
diseases“ OR CVD OR CHD OR CAD OR OR MI OR
atherosclerosis OR “heart failure” OR “heart diseases“
myocery “OR“ coronary art infarction “OR“ angina pec-
toris “OR“ ischemic heart “). These keywords and their
possible combination were searched in international da-
tabases, and for Persian databases the search was done
using the Persian equivalent of the keywords expressed.
Moreover, searches in Google Scholar were conducted
separately both in English and in Persian, in order to
identify gray literature. Assessment of relevant webpages,
as well as analysing the references within collected
sources were also conducted.
Selection criteria, and article assessment
After the search process, all the articles were collected in
the EndNote software,and the duplicate articles were de-
leted. Criteria for entering articles into the study were:
1- case control studies and 2- cohort research, and 3-
studies that link the genes expressing cytokines and car-
diovascular disorders; Criteria for excluding the studies
were: 1- cross-sectional studies 2- case reports 3- inter-
ventional studies 4-letters to editor 5- studies where
their full text were not available, and 6- studies in which
the study population had an underlying disease.
Then, a list of article titles and abstracts was put to-
gether, and after redacting the details of the articles,
their full texts were provided to the reviewers. Each art-
icle was independently reviewed by two reviewers, and
any disagreement was then reviewed by a third reviewer.
Fig. 1 Immune cells, smooth muscle cells, and endothelial cells synthesize interleukin-6 from human 7th chromosome. In the liver, interleukin 6
binds to the IL-6 membrane receptor, activating gp130 and stimulating the classical signaling pathway
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For assessing the quality of the collected articles,
STROBE checklist was used. This checklist includes 22
criteria, 18 of which are used publicly for all observa-
tional studies and 4 items are used exclusively based on
the type of study. The checklist criteria include study ob-
jectives, determining the appropriate sample size, type of
study, sampling method, research community, data col-
lection method, defining variables and how to review the
samples, study data collection tools, study objectives, the
statistical test used, and the results of the study. The
maximum score for articles could be 31, and articles
with a score below 14 were excluded from the study.
The studies were then meta-analysed using the four step
of (i.e. identification of articles, screening, review of ad-
mission criteria, and finally articles submitted to meta-
analysis) PRISMA 2009 process (Fig. 2).
Statistical analysis
In this study, the heterogeneity of studies was examined
using the I2 test. In general, heterogeneity is classified
into three categories, heterogeneity less than 25% (low
heterogeneity), between 25 to 75% (medium heterogen-
eity) and above 75% (high heterogeneity). Data were
meta-analysed using the Comprehensive Meta-analysis
software (Biostat, Englewood, NJ, USA version 3).
Results
This study examined the relationship between IL-
6572G> C and IL-6174 C> G gene polymorphism and
coronary artery disease following a systematic review
and meta-analysis. After searching various databases,
2619 articles were collected. 317 articles from EMBASE,
399 articles from ProQuest, 345 articles from PubMed,
149 articles from Science Direct, 313 articles from Sco-
pus, 395 articles from Web of Science, 6 articles from
SID, 10 articles from Irandoc. and 685 articles from
Google Scholar. 786 duplicate articles were removed,
and subsequently 1358 other articles were deleted after
reviewing their title and abstract. 475 articles were then
entered the secondary evaluation phase. By examining
the full text of the articles in terms of relevance and
quality, another 438 articles were excluded. and finally
37 articles entered the meta-analysis stage (Tables 1
and 2) [28–61].
Gene Interleukin-6 (IL-6) 174G> C
Investigation of heterogeneity and publication bias (GG, CG,
CC genotypes)
The heterogeneity of the studies was investigated
using I2 test and based on this test, the heterogeneity
in GG, CG and CC genotypes were calculated as I2 =
59.1%, I2 = 79.2%, and I2 = 70% respectively The
Fig. 2 PRISMA flow diagram illustrating the four step process for identifuing teh articles for meta-analysis
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results demonstrate a high level of heterogeneity
among articles, and therefore the random effects
model was used to amalgamate the results from these
studies. The publication bias was calculated using the
Egger’s test; the test did not find bias in any of the
genotypes, since the results were not statistically sig-
nificant (P> 0.05) (Table 3). One of the most import-
ant reasons for the high heterogeneity in the study is
Table 1 Characteristics of studies that entered the meta-analysis stage
Rows Name [references] country Year of
publish
Mean age of case
group (SD)








Brazil 2011 54.9 + 1.1 54.9 + 1.1 72 71
2 Ansari, Wafa Munir [29] Pakistan 2017 42±3.80 42±3.80 340 310
3 Babu, Baddela M. V.
Srikanth [30]
India 2012 53.56 ±11.72 52.62 ± 8.45 651 432
4 Banerjee, Indranil [31] India 2009 56.3 ± 12.1 56.0 ± 9.5 210 232
5 Basso, F [32]. America 2002 56±5 56±5 498 1108
6 Bhanushali, A. A [33]. India 2013 48±11 50±11 100 150
7 Chen, H [34]. China 2018 61.00 ± 10.49 60.37 ± 10.38 322 429
8 Elsaid, A [35]. Egypt 2014 53.54 ± 9.1 45.3 ± 7.2 108 143
9 Fan, W. H [36]. China 2011 52.1 ± 6.8 52.3 ± 8.8 84 130
10 Fragoso, J. M [22]. Mexico 2010 58.88 ±11.7 56.03 ±4.13 284 247
11 Galimudi, R. K [37]. India 2014 65±5 64±6 200 200
12 Gao, Y. L. [38] China 2016 61.50±10.53 52.54±10.65 275 286
13 Ghazouani, Lakhdar [39] Tunisia 2010 58.1±12.0 56.7±14.1 418 406
14 Humphries, S. E [40]. England 2001 56·7±3·6 56·0±3·4 162 2589
15 Indumathi, B [41]. India 2019 56.00 ± 12.00 – 265 205
16 Jabir, N. R [42] Saudi
Arabia
2017 60.6±8.85 47.7±5.06 90 89
17 Jia, X. W [43]. China 2010 – – 231 210
18 Jun, M [44]. China 2017 63.5±13.6 64.2±14.1 860 862
19 Li, L. [45] China 2015 – – 365 365
20 Maitra, A [46]. India 2008 57.17 ± 9.22 45.53 ± 5.98 46 40
21 Mao, L. [47] China 2016 62.65 ± 9.72 56.82 ± 9.80 224 260
22 Mastana, S [48]. India 2017 49.51±11.06 45.02±14.46 143 136
23 Mitrokhin, V [49]. Russia 2017 70.37±13.45 74.94±7.43 198 116
24 Nauck, M [50]. Germany 2002 63.77±9.89 58.30±11.83 2575 729
25 Omer, W [51]. Turkey 2016 42 ±3.80 39 ± 7.8 340 310
26 Phulukdaree, Alisa [52] India 2013 37.5 – 41 61
27 Rios, D. L. S [53]. Brazil 2010 – – 414 253
28 Sarecka-Hujar, Beata [54] Poland 2008 43.8±6.1 35.4±10.4 177 202
29 Satti, H. S [55]. Pakistan 2013 46.4 ± 18.7 35.2 ± 17.4 36 52
30 Sekuri, C [56]. Turkey 2007 46.3 ±7.8 44.3 ±7.2 115 105
31 Shabana, N. A [4]. Pakistan 2018 59.10 ± 12.64 56.0 ± 10.4 404 219
32 Sun, G. Q [57]. China 2014 61.2 ± 8.5 56.4 ± 11.6 296 327
33 Tong, Z. C [58]. China 2013 61.4±8.7 60.6±9.6 326 341
34 Tütün, Ufuk [59] Turkey 2006 29.3± 4.3 31.1 ± 4.0 21 50
35 Wang, K [60] China 2015 65.4 ± 8.4 64.9 ± 8.2 402 402
36 Yang, H. T [61]. China 2015 – – 410 410
37 Yao, H. M [17]. China 2016 62.64±8.43 61.43±7.85 275 296
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Table 2 Odds ration of studies that entered the meta-analysis stage (IL-6 -174 G>C and coronary and IL-6572 C>G and coronary
artery disease)

























































8 4 2.257 (0.670–
7.609)















3 4 1.129 (0.247–
5.155)






56 27 3.135 (1.931–
5.089)






















26 18 1.511 (0.800–
2.854)
















10 7 1.397 (0.527–
3.706)






25 470 0823 (0.531–
1.275)






3 3 0.771 (0.154–
3.860)






3 3 0989 (0.194–
5.034)






72 48 1.549 (1.062–
2.262)






39 15 2.791 (1.510–
5.160)





0 3 0.115 (0.006–
2.301)
Mao, L. 142 193 0.601 45 45 1.201 37 22 2.140 (1.221–
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1 1 0.951 (0.059–
15.352)






36 26 0.769 (0.437–
1.355)






499 144 0.976 (0.794–
1.201)
















1 8 0.166 (0.020–
1.378)










92 105 1 (0.668–
1.497)
42 37 1.387 (0.844–
2.281)















5 7 0636 (0.185–
2.824)






99 33 1.830 (1.185–
2.824)






44 28 1.865 (1.128–
3.082)






38 23 1.824 (1.061–
3.136)















51 78 1.657 (1.129–
2.432)






49 25 2.090 (1.264–
3.456)































425 959 0.905 (0.668–
1.224)






43 33 1.849 (1.146–
2.985)
Salari et al. Genes and Environment            (2021) 43:1 Page 7 of 16
the difference in the volume of case and control sam-
ples in the studied studies. The number of samples in
each study is adjusted according to the objectives of
that study and as reported in Table 1 among all Stud-
ies are different.
Meta-analysis of genotype GG
The total number of samples entered in the study was 11,
463 and 12,316 for the case and control groups respectively.
The odds ratio of GG genotype in patients with coronary
artery disease based on meta-analysis of 35 studies was 0.8
(95% CI:0.72–0.89), which tends to reduce the risk of CAD
by 0.2, meaning that people with this genotype are 20% less
likely than others to tends coronary artery disease (Fig. 3).
Figure 3 illustrates the odds ratio based on the model of
random effects. The black small rectangle is the odds ratio,
and the length of the line on which the square is located, is
a representative of the 95% significance level for each study.
The diamond sign represents the odds ratio for all studies.
Table 2 Odds ration of studies that entered the meta-analysis stage (IL-6 -174 G>C and coronary and IL-6572 C>G and coronary
artery disease) (Continued)






4 3 2.117 (0.462–
9.706)






115 108 0.876 (0.620–
1.37)






27 22 1.306 (0.725–
2.354)






135 2224 0.821 (0.535–
1.259)






59 54 1.234 (0.671–
2.266)






22 15 1.368 (0.690–
2.714)






96 43 2.393 (1.648–
3.475)






68 43 1.715 (1.134–
2.592)














33 27 1.491 (0.866–
2.567)






182 104 1.313 (0.598–
2.881)






190 215 0.934 (0.672–
1.298)





37 43 0.887 (0.555–
1.417)






39 29 1.382 (0.837–
2.283)
Table 3 Heterogenity and publication bias in the studied
genotypes
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Meta-analysis of genotype CG
The total number of samples entered in the study was
11,463 and 12,316 for the case and control groups re-
spectively. The odds ratio of CG genotype in patients
with coronary artery disease based on meta-analysis of
35 studies by 1.16 (95% CI:1.02–1.32), which indicates
the increasing effect of CG genotype with 0.16, meaning
that people with this genotype are 16% more likely than
others to have coronary artery disease (Fig. 4). Figure 4
illustrates the odds ratio based on the model of random
effects. The black small rectangle is the odds ratio, and
the length of the line on which the square is located, is a
representative of the 95% significance level for each
study. The diamond sign represents the odds ratio for all
studies.
Meta-analysis of genotype CC
The total number of samples entered in the study was
11,104 and 11,890 for the case and control groups re-
spectively. The odds ratio of CC genotype in patients
with coronary artery disease based on meta-analysis of
33 studies was 1.48 (95% CI:1.21–1.91), which indicates
the increasing effect of CC genotype by 0.48, meaning
that people with this genotype are 48% more likely than
others to have coronary artery disease (Fig. 5). Figure 5
illustrates the odds ratio based on the model of random
effects. The black small rectangle is the odds ratio, and
the length of the line on which the square is located, is a
representative of the 95% significance level for each
study. The diamond sign represents the odds ratio for all
studies.
Gene Interleukin-6 (IL-6) 572C> G
Investigation of heterogeneity and publication bias (GG, CG,
CC genotypes)
The heterogeneity of the studies was investigated using
I2 test and based on this test, the heterogeneity in GG,
CG and CC genotypes were calculated as I2 = 59.6%, I2
= 62.4%, and I2 = 87.7% respectively The results demon-
strate a high level of heterogeneity among articles, and
therefore the random effects model was used to amal-
gamate the results from these studies. The publication
bias was calculated using the Egger’s test; the test did
not find bias in any of the genotypes, since the results
were not statistically significant (P> 0.05) (Table 4).
Meta-analysis of genotype GG
The total number of samples entered in the study was
4663 and 7801 for the case and control groups respect-
ively. The odds ratio of GG genotype in patients with
coronary artery disease based on meta-analysis of 16
studies was 1.27 (95% CI:1.05–1.55), which indicates the
Fig. 3 The odds ratio of GG genotype in patients with coronary artery disease
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Fig. 5 The odds ratio of CC genotype in patients with coronary artery disease
Fig. 4 The odds ratio of CG genotype in patients with coronary artery disease
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increasing effect of GG genotype by 0.27, meaning that
people with this genotype are 27% more likely than
others to have coronary artery disease (Fig. 6). Figure 6
illustrates the odds ratio based on the model of random
effects. The black small rectangle is the odds ratio, and
the length of the line on which the square is located, is a
representative of the 95% significance level for each
study. The diamond sign represents the odds ratio for all
studies.
Meta-analysis of genotype CG
The total number of samples entered in the study was
4663 and 6615 for the case and control groups respect-
ively. The odds ratio of CG genotype in patients with
coronary artery disease based on meta-analysis of 16
studies was 1.21 (95% CI:1.04–1.41), which indicates the
increasing effect of CG genotype by 0.21, meaning that
people with this genotype are 21% more likely than
others to have coronary artery disease (Fig. 7). Figure 7
illustrates the odds ratio based on the model of random
effects. The black small rectangle is the odds ratio, and
the length of the line on which the square is located, is a
representative of the 95% significance level for each
study. The diamond sign represents the odds ratio for all
studies.
Meta-analysis of genotype CC
The total number of samples entered in the study was
4165 and 7801 for the case and control groups respect-
ively. The odds ratio of CC genotype in patients with
coronary artery disease based on meta-analysis of 16
studies was 0.85 (95% CI:0.61–1.18), which tends to re-
duce the risk of CAD by 0.15, meaning that people with
this genotype are 15% less likely than others to tends
coronary artery disease (Fig. 8). Figure 8 illustrates the
odds ratio based on the model of random effects. The
black small rectangle is the odds ratio, and the length of
the line on which the square is located, is a representa-
tive of the 95% significance level for each study. The dia-
mond sign represents the odds ratio for all studies.
Discussion
Cardiovascular disorders, including coronary artery dis-
ease, have a very complex etiology. However, the impact
of environmental and genetic factors on the occurance
of these diseases has been verified. Factors influencing
the incidence of this disease are divided into two cat-
egories: modifiable and unmodifiable [62, 63]. In other
words, factors such as diabetes, smoking, obesity, blood
pressure and stress are among the factors that can be
corrected. Genetics, age and gender are considered as
unmodifiable factors. Known genetic factors slightly in-
crease the risk of coronary artery disease. However, gen-
etic patterns that greatly increase the risk of CAD are
still unknown [38, 64]. However, genetic susceptibility
that exposes individuals to abnormal levels of athero-
sclerosis also intensified the risk of developing CAD
[62–65].
Table 4 Heterogenity and publication bias in the studied
genotypes




Fig. 6 The odds ratio of GG genotype in patients with coronary artery disease
Salari et al. Genes and Environment            (2021) 43:1 Page 11 of 16
The development of techniques in the field of biomol-
ecules has made it possible to conduct comrehensive
studies on polymorphisms. Examination of the poly-
morphism of cytokine genes, including interleukin-6, has
shown that the production of these proteins varies from
one person to another. It has also been shown that dif-
ferent pathways of Interleukin-6 (IL-6) protein expres-
sion have specific biological roles in the development of
CAD susceptibility [50].
In this study, the relationship between two different
polymorphisms of the Interleukin-6 (IL-6) gene was
investigated by a systematic review and meta-analysis.
After analyzing data related to Interleukin-6 (IL-6)
174G> C polymorphism and its relationship to CAD, it
was highlighted that CC genotype has a more increasing
effect (with 48% higher likelihood) than other genotypes.
The heterozygous genotype also increases the chances of
developing CAD by 16%, whereas the GG genotype of-
fers a 20% protective effect; in other words, the risk of
developing CAD in carriers of this genotype is 20%
lower than others. It has been observed that in this poly-
morphism, allele C acts as a risk factor for coronary
Fig. 7 The odds ratio of CG genotype in patients with coronary artery disease
Fig. 8 The odds ratio of CC genotype in patients with coronary artery disease
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artery disease. Moreover, by analyzing the information
related to Interleukin-6 (IL-6) -572C> G polymorphism,
it was found that CC genotype exerts its protective effect
by 15% in this polymorphism, whereas CG and GG ge-
notypes increase the risk of developing CAD by 21 and
27% respectively. In this polymorphism, allele G in-
creases the risk of CAD and is considered as a risk factor
[50–55].
A study by González-Castro et al. (2019) demonstrated
that the Interleukin-6 (IL-6) 174 gene was associated
with CAD, highlighting that the homozygous genotype
and the heterogeneous genotype increased the risk of
developing CAD by up to 50 and 10% respectively. Ac-
cording to this study, dominance will increase the risk of
CAD by 23%. This gene also generally increases the risk
of cardiovascular disease [66]. Zheng et al., (2012), after
reviewing 27 studies with systematic review and meta-
analysis, argued that there was no association between
Interleukin-6 (IL-6) -174G> C polymorphism and an in-
creased risk of Coronary Heart Disease (CHD) [67]. Ac-
cording to another meta-analysis conducted by Zhang
et al. (2018), after reviewing 46 studies related to
Interleukin-6 (IL-6) 174 G> C, it was stated that the GG
genotype exerts a 19% protective effect. CG and CC ge-
notypes also increase the risk of CAD by 5 and 35% re-
spectively. In this study, the relationship between
Interleukin-6 (IL-6) -572 and CAD was also measured.
According to the analysis, the GG genotype has a
protective effect and the CG and GG genotypes have an
increasing effect. Nevertheless, the results of the analysis
of CC and GG genotypes in the Interleukin-6 (IL-6) 572
gene in the study are different from the results of our
analysis [68]. The study of Aker et al. (2009) also showed
that in Interleukin-6 (IL-6)-174 polymorphism, CC
genotype increased the risk of CAD more than CG and
GG genotypes [69].
According to literature, factors such as inflammation
and activation of immune cells play a role in the devel-
opment of coronary artery syndrome [70]. That is to say,
inflammation and atherosclerosis have a similar patho-
physiological pathway [65].
It is possible that small changes in serum levels of in-
flammatory agents may be a factor in the clinical course
of the disease [71] Inflammatory cytokines, such as in-
terleukins, are involved in some CAD predisposing fac-
tors. These include LDL cholesterol, arterial blood
pressure, and diastolic heart function. Existing research
works show that high Interleukin-6 (IL-6) concentration
is directly related to the development of CAD [72]. Ac-
cording to a study by Toutouzas, et al. (2017) various
Interleukin-6 (IL-6) 174 G> C polymorphism genotypes
are associated with serum Interleukin-6 (IL-6) levels.
Moreover, according to the same research, the CC geno-
type of this polymorphism increases serum IL-6 levels
more than other genotypes. In other words, the C allele
in this polymorphism has an increasing effect on the
Fig. 9 The relationship between IL-6, CRP and cardiovascular disease: Interleukin 6 affects CID and causes CRP and fibrinogen production. These
two substances cause the formation of fibrosis plaque in the coronary arteries. Furthermore, the effect of ischemic myocardial infarction on IL-6
production and the role of IL-6 in cardiovascular disease has been shown to be two-sided
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serum level of Interleukin-6 (IL-6), increasing the risk of
CAD development, and by affecting the formation of
coronary plaques, it increases the clinical symptoms in a
multi-year course [71]. Moreover, another research work
demonstrated that Interleukin-6 (IL-6) 174 polymorph-
ism had no significant correlation with the serum IL-6
levels [73].
Plasma concentrations of IL-6 can reflect the severity
of inflammation caused by fibrous plaques. Therefore,
by monitoring the concentration of IL-6 in a person’s
bloodstream, the risk of developing CAD can be mea-
sured [74]. Studies show that IL-6 is a biomarker with
better sensitivity and characteristics than CRP for the
diagnosis of cardiovascular disease [75]. A study by
Lindmark et al. (2001) argue that IL-6 levels also play a
role in mortality from heart disease, in orther words, the
higher the plasma levels of this substance, the higher the
mortality rate (Fig. 9) [76].
As mentioned earlier, CAD lesions are caused by fi-
brous plaques surrounded by lipids. Early atherosclerotic
plaques are composed of CRP that may be similar to
monocytes over time. In other words, the expression of
CRP and adhesion molecules can stimulate chemokines
and co-activate endothelial cells with lipopolysaccha-
rides. Adhesive molecules are known to mediate T cells
that are involved in creating immune responses to in-
flammation [38, 77].
Existing research works demonstrate that Interleukin-
6 (IL-6) gene polymorphisms affect plasma levels of
hsCRP and fibrinogen (47). High levels of CRP are
known to be a risk factor for development of CAD.
Moreover, risks associated with other various factors
such as obesity and high blood pressure are seen in these
people [65]. One common approach is to measure serum
concentrations of anti-inflammatory agents such as hs
CRP and interleukin 6. Both substances are considered
as a risk factor for development of heart disease, and as-
sessment of their levels are commonly used to determine
the risk of inflammation [78]. Klimushina et al. (2019)
argued that women carrying the GL Interleukin-6 (IL-6)
174 polymorphism had higher serum hsCRP levels than
the CC genotype [73]. A study by Champan et al. (2003)
which was conducted in Australia found that CG and
CC genotypes increased the probability of developing fi-
broid plaques in the Australian population by 1.39 and
2.22 times respectively [78].
Limitations
One of the limitations of this study was the lack of ac-
cess to the full text of a number of studies; moreover, ar-
ticles which were in a language other than English or
Persian were considered for this systematic review and
meta-analysis.
Conclusions
This study demonstrated that there is an association be-
tween IL-6174 and IL-6572 genes and the occurrence of
coronary artery disease. According to the analyses con-
ducted in this work, the protective effect of GG genotype
in IL-6174 gene and CC genotype in IL-6572 gene were
illustrated. It was also stated that the CG and CC geno-
types of the IL-6174 gene have an increasing effect on
coronary artery disease. Furthermore, it was observed
that CG and GG genotypes in the IL-6572 gene increase
the probability of developing CAD. And in general,
people with the CC genotype of the IL-6174 gene are
more at risk of developing CAD than others. In future
studies, we can compare the plasma levels of
interleukin-6 with each polymorphism and the risk of
developing CAD.
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